This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
A Zero Based Budgeting mindset centers on intentional spending and goal alignment, transforming how you think about every dollar and decision.
15,946 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
A forward-looking look at Compugen's 2025 earnings. Learn how pipeline progress, partnerships, and cash runway could ...
Analysts push higher targets for AMD as data center AI demand accelerates. A stock price prediction: strong consensus...
Credit investors are increasingly worried about an AI bubble. A Bank of America survey shows the concern rising fast,...
The U.S. has removed foreign-access restrictions on Anthropic’s Claude 3.5 and Fable 5, signaling a renewed AI leader...
As energy markets tilt between supply concerns and resilient cash flow, March can be a strategic moment to position f...
XRP’s derivatives market shows a rare drop in open interest while large holders accumulate on-chain. The move could h...
JPMorgan CEO Jamie Dimon dismissed Donald Trump’s $5 billion debanking lawsuit as meritless, but said he understands ...
Streamex introduces GLDY, a gold-backed token, into regular brokerage accounts, offering a 3.5% yield paid in gold an...
C3.ai saw a sharp drop after its latest results, renewing debate about whether the stock is a value play or a value t...
Bitwise CIO Matt Hougan argues that Strategy's STRC selloff reflects end-of-cycle deleveraging preceding a bitcoin bo...
Cisco is betting on AI infrastructure and recurring revenue to escape dot-com era fears. With rising ARR, rising subs...